The novel coronavirus is still a part of our lives and it still makes reality a nightmare. There’s some news about new treatments that might be able to make your day better, so check it out below.
AstraZeneca covid treatment
The press agency Reuters just noted that AstraZeneca said on Monday its antibody-based cocktail to prevent and treat covid 19 retained neutralizing activity against Omicron coronavirus variants, including the highly contagious BA.2 sub-variant, in an independent lab study.
AstraZeneca monoclonal antibody therapy
At the end of 2021, we were revealing that there are more and more predictions about the path that the pandemic will be taking in the near future. Now, it’s been revealed that brand new studies are addressing the efficiency of AstraZeneca’s monoclonal antibody drugs.
It’s been just revealed that the drug is effective against the covid 19 variant Omicron, according to a new report.
“The company’s EVUSHELD retains neutralization activity against omicron, according to ‘live’ virus neutralization data from both University College Oxford and Washington University School of Medicine,” ABC News reported.
The online publication Daily Wire revealed that AstraZeneca’s treatment was authorized on December 8 but used to prevent covid 19 “among people who are immune compromised, or people who are allergic to vaccine components. It is not authorized as a way to treat COVID-19 among people who have already tested positive,” ABC reported.
The reports continued and said:
“There are three monoclonal antibody treatments currently authorized to treat people who already have COVID-19. Two of those treatments — those made by Eli Lilly and Regeneron — appear to have very little activity against omicron. A third treatment, made by Vir and GlaxoSmithKline, appears to work against omicron but is currently in short supply. The companies are working to scale up production.”
Stay tuned for more news, and also make sure to stay safe.